EN DE
Watch Nanogroup SA for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Nanogroup SA (NNG) fair value: what the stock is really worth

As of Nov 10, 2026: fair value (intrinsic value) of Nanogroup SA stock PLN 1.61, price PLN 2.21, that is 27.0% below the price, quality 27 out of 100. Rating: overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare PL · ISIN PLNNGRP00011

NS Nanogroup SA logo Thin data Nov 10, 2026

Nanogroup SA

NNG · WAR
Expensive, weak quality

Our calculation puts a fair price 27% below what the stock costs today.

Low debt
Revenue last quarter +18% vs. a year ago.
Fair value 1.61 PLN · Overvalued
Quality 27/100
Weak Growth (revenue 5y −64.1 %/yr in PLN)
Negative free cash flow
Trails peers (2/8)
Narrow moat 9/100 · thin data
Thin data
Estimate
Watch Nanogroup SA for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

5.25 PLN 0.8960 PLN Fair Value 1.61 PLN Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.

How to read this chart

60‑month range 0.8960 PLN – 5.25 PLN · fair‑value band 1.21 PLN – 2.01 PLN · the 2.21 PLN price screens above the 1.61 PLN fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 10, 2026.

Follow Nanogroup in your weekly email

Every Wednesday you see whether Nanogroup is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

NanoGroup S.A. operates as a biotechnology company in Poland. It engages in the production of medicines and other pharmaceutical products, and research and development work in the field of biotechnology and other natural and technical sciences.

Show moreShow less

The company is also involved in technical research and analysis. In addition, it manages a portfolio of companies that manage projects to meet the needs of modern medicine in the field of oncology and transplantology. The company was founded in 2016 and is based in Warsaw, Poland.

Stock analysis

Nanogroup SA (NNG) currently trades at 2.21 PLN, while our estimate is 1.61 PLN, 27% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: 1.21 PLN (bear) to 2.01 PLN (bull), the price of 2.21 PLN sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 27/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.

Nanogroup SA reported revenue of 0 PLN in FY2025 versus 492K PLN in FY2021. Reported net income was −9.4M PLN in FY2025.

Key figures

Market cap 94.0M PLN (≈ $24.0M) Micro · P/S ratio 34.9 · EPS (TTM) −0.3100 PLN · Return on equity −61.1% · Return on assets (EBIT) −39.5% (5-year average) · Operating margin −145% · Revenue (TTM) 2.9M PLN · Revenue growth (YoY) +18.2%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 9 out of 100 (low confidence).

What moves the price

The share trades about 29% below its 52-week high and at its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −27%, NNG screens richer than that median.

Fair Value

Bear 1.21 PLN Fair Value 1.61 PLN Bull 2.01 PLN
Price 2.21 PLN · Downside -27.0%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 27/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 0
How much profit the company makes from its sales and capital
Quality Growth 42
Are margins and returns getting better?
Cashflow 29
Do the profits arrive as real cash?
Financial strength 55
Debt, balance sheet and risk of trouble
Investment 32
Does it invest with discipline instead of growing at any price?
Low Volatility 82
How calm the share price moves, does not count
Price momentum 32
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 10
Distance to the 52-week high, does not count
New shares 0
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 0/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
+4.0%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−83.8%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−64.1%
Revenue growth 9 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−13.1%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−485.8% (2019) → −246,564.3% (2024)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

NNG screens overvalued: fair value 27% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare Nanogroup SA with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 849 stocks

Beats the industry median on 2/7 measures
Overall it trails its industry peers.
Valuation
Quality Score 27 · Bottom 25%
Fair Value upside −27.0% · Below median
Profitability
Return on assets −23.3% · Below median
Operating margin (12 months) −144.8% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) 18.2% · Above median
Balance sheet
Debt / equity 0.03× · Below median

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 10.82× · book value is mostly goodwill ⓘGoodwill and other intangible assets are larger than the equity. The book value mainly reflects prices paid for past acquisitions, so we do not rank this P/B against the peer group.
P/S (12 months) 32.49× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 0
FUTURE (revenue growth)91 · sector 0
PAST (return on equity)0 · sector 0
HEALTH (low debt)98 · sector 96
DIVIDEND (yield)0 · sector 20

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Regeneron Pharmaceuticals, Inc REGN $916.06 $1,275 +39% vs NNG
Samsung Biologics Co 207940 1,468,000 KRW 1,661,000 KRW +13% vs NNG
Vertex Pharmaceuticals Incorporated VRTX $547.89 $601.80 +10% vs NNG
Genmab A/S GMAB kr 3,581 kr 3,880 +8% vs NNG
argenx SE ARGX $971.55 $908.40 −7% vs NNG
CSL Limited CSL A$201.68 A$181.40 −10% vs NNG
Moderna, Inc MRNA $250.83 $158.70 −37% vs NNG
BeOne Medicines AG 6160 HK$252.20 HK$152.80 −39% vs NNG
Celltrion, Inc 068270 203,000 KRW 74,945 KRW −63% vs NNG
Royalty Pharma plc RPRX $69.45 $19.01 −73% vs NNG

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Nanogroup SA: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Nanogroup SA Fair Value". https://www.fairvalue-calculator.com/stock/NNG

Frequently asked questions

Is Nanogroup SA (NNG) overvalued or undervalued?
As of Nov 10, 2026, our estimate of fair value is 1.61 PLN versus a price of 2.21 PLN, about 27% lower (overvalued).
What is the fair value of NNG?
Our estimate for Nanogroup SA is 1.61 PLN (as of Nov 10, 2026), built from audited fundamentals. The current price: 2.21 PLN.
What is the quality score of NNG?
Nanogroup SA has a Quality Score of 27/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Nanogroup SA (NNG)?
Our calculated price target is the estimate of 1.61 PLN (as of Nov 10, 2026). Cautious scenario 1.21 PLN, optimistic scenario 2.01 PLN. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Nanogroup SA stock forecast for 2026?
Our estimate puts fair value at 1.61 PLN, about 27% lower versus a price of 2.21 PLN (overvalued). Cautious scenario 1.21 PLN, optimistic scenario 2.01 PLN. The calculation is refreshed regularly with new filings.
What is the revenue of Nanogroup SA (NNG)?
Nanogroup SA reported trailing-twelve-month revenue of about 2.9M PLN (latest available figure, as of Nov 10, 2026).
What is the intrinsic value of Nanogroup SA (NNG)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Nanogroup SA it is 1.61 PLN per share (as of Nov 10, 2026), against a price of 2.21 PLN.
Is Nanogroup SA stock overvalued or undervalued in 2026?
As of Nov 10, 2026, NNG trades above its calculated fair value: price 2.21 PLN, fair value 1.61 PLN, a gap of about −27% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of NNG?
No. The price is what the market pays today (2.21 PLN); the fair value is what the company's own numbers justify (1.61 PLN). For Nanogroup SA the two are 0.5950 PLN per share apart. That gap is exactly why we show both numbers side by side.
How much is Nanogroup SA worth?
The market values Nanogroup SA at about 94.0M PLN (market capitalisation, as of Nov 10, 2026). Per share that is 2.21 PLN; our models calculate a fair value of 1.61 PLN per share.
What do the bullish and bearish scenarios say about NNG?
Our models span a range for Nanogroup SA: cautious scenario 1.21 PLN, base 1.61 PLN, optimistic 2.01 PLN per share (as of Nov 10, 2026, price 2.21 PLN). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Nanogroup SA (NNG)?
Balance-sheet figures for Nanogroup SA (as of Nov 10, 2026): return on equity −61.1%, debt of 0.03 per unit of equity. They feed the Quality Score of 27/100, which measures business quality independently of the share price.
How far is NNG from its 52-week high?
Nanogroup SA trades at 2.21 PLN, about 29% below its 52-week high of 3.12 PLN and at the low of 2.21 PLN (as of Nov 10, 2026). Distance from the high says nothing about value: that is what the fair value of 1.61 PLN is for.
Which stocks are comparable to Nanogroup SA?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Moderna, Inc, Regeneron Pharmaceuticals, Inc, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Nanogroup SA stock attractive at the current price?
The data as of Nov 10, 2026: price 2.21 PLN, calculated fair value 1.61 PLN (−27%), Quality Score 27/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 15.1% above its aggregate fair value. Nanogroup SA itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Nanogroup SA (NNG)?
The closing price on Nov 10, 2026 was 2.21 PLN. Our estimate is 1.61 PLN, about 27% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Nanogroup SA right now?
The price sits above even our optimistic bull case (2.01 PLN). The favourable scenario is already priced in. Weak quality (27/100) and above fair value at the same time, the margin of safety is missing on both counts. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of Nanogroup SA

How large is the market capitalisation of Nanogroup SA (NNG)?
The market capitalisation of Nanogroup SA is 94.0M PLN (≈ $24.0M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Nanogroup SA (NNG)?
The price-to-sales ratio of Nanogroup SA is 34.9 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Nanogroup SA (NNG)?
Earnings per share at Nanogroup SA are −0.3100 PLN. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Nanogroup SA (NNG)?
The return on equity (ROE) of Nanogroup SA is −61.1% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Nanogroup SA (NNG)?
On an EBIT basis the return on assets of Nanogroup SA is −39.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Nanogroup SA (NNG)?
The operating margin of Nanogroup SA is −145% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Nanogroup SA (NNG)?
Revenue at Nanogroup SA is growing +18.2% versus a year earlier. How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Nanogroup SA (NNG) generate?
The free cash flow of Nanogroup SA is −23.6M PLN (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Nanogroup SA (NNG) hold?
Nanogroup SA holds more cash than debt, 15.5M PLN net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Nanogroup SA in the live analysis

One click puts Nanogroup SA on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.